Pexidartinib

Last Updated: 04/28/2026

Need to find the closest trial?
Sort By Distance
Save trials for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
3 clinical trials found

    Phase I Trial of TURALIO (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCT)

    Phase I Trial of TURALIO (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCT)

    Who is this study for: Child to adult patients with Recurrent or Refractory Solid Tumors or Acute Leukemia
    Enrollment Status: Recruiting
    Publish Date: April 14, 2026
    Intervention Type: Drug
    Study Drug: PLX3397
    Study Phase: Phase 1

    Background: \- Some people with cancer have solid tumors. Others have refractory leukemia. This may not go away after treatment. Researchers want to see if a drug called TURALIO(R) can shrink tumors or stop them from growing.

    I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

    I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

    Who is this study for: Patients with Breast Cancer
    Enrollment Status: Recruiting
    Publish Date: March 13, 2026
    Intervention Type: Drug
    Study Drugs: Standard Therapy, AMG 386 +/- Trastuzumab, AMG 479 (Ganitumab)+Metformin, MK-2206 +/- Trastuzumab, AMG 386+Trastuzumab, T-DM1+Pertuzumab, Pertuzumab+Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 Cycle, Talazoparib+Irinotecan, Patritumab+Trastuzumab, Pembrolizumab - 8 Cycle, SGN-LIV1A, Durvalumab+Olaparib, SD-101+Pembrolizumab, Tucatinib+Trastuzumab and Pertuzumab, Cemiplimab, Cemiplimab+REGN3767, Trilaciclib +/- Trastuzumab+Pertuzumab, SYD985 ([vic-]Trastuzumab Duocarmazine), Oral Paclitaxel+Encequidar+Dostarlimab (TSR-042)+Carboplatin +/- Trastuzumab, Oral Paclitaxel+Encequidar+Dostarlimab (TSR-042) +/- Trastuzumab
    Study Phase: Phase 2

    Summary: The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.

    A Long-term Study to Further Evaluate the Risk of Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

    A Long-term Study to Further Evaluate the Risk of Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

    Enrollment Status: Recruiting
    Publish Date: October 06, 2025
    Intervention Type: Drug

    Summary: A study to evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon optional liver biopsy information among patients who received or are receiving TURALIO™ (pexidartinib) and experience hepatotoxicity.

    Showing 1-3 of 3

    Last Updated: 04/28/2026